Objective IBD prevalence is estimated to be rising, but no detailed, recent UK data are available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to establish the current, and project future, prevalence in Lothian, Scotland. Design We conducted an all-age multiparameter search strategy using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997–2018), IBD pathology coding (1990–2018), primary and secondary care prescribing data (2009–2018) and a paediatric registry, (1997–2018) to identify ‘possible’ IBD cases up to 31/08/2018. Diagnoses were manually confirmed through electronic health record review as per Lennard-Jones/Porto criteria. Autoregressive integrated moving average (ARIMA) regression was applied to forecast prevalence to 01/08/2028. Results In total, 24 601 possible IBD cases were identified of which 10 499 were true positives. The point prevalence for IBD in Lothian on 31/08/2018 was 784/100 000 (UC 432/100 000, Crohn’s disease 284/100 000 and IBD unclassified (IBDU) 68/100 000). Capture–recapture methods identified an additional 427 ‘missed’ cases (95% CI 383 to 477) resulting in a ‘true’ prevalence of 832/100 000 (95% CI 827 to 837). Prevalence increased by 4.3% per year between 2008 and 2018 (95% CI +3.7 to +4.9%, p80 years of age. Conclusions We report a rigorously validated IBD cohort with all-age point prevalence on 31/08/2018 of 1 in 125, one of the highest worldwide.
Summary: Objective: It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has translated into the causes and rates of hospitalisation, particularly in an era of increased biologic prescribing. We aimed to analyse these trends in a population‐based IBD cohort over the last 10 years.Design: The Lothian IBD registry is a complete, validated, prevalent database of IBD patients in NHS Lothian, Scotland. ICD‐10 coding of hospital discharge letters from all IBD patient admissions to secondary care between 1 January 2010 and 31 December 2019 was interrogated for admission cause, with linkage to local/national data sets on death and prescribed drugs.Results: Fifty‐seven per cent (4673/8211) of all IBD patients were admitted to secondary care for >24 h between 1 January 2010 and 31 December 2019. In patients 60 years (19% of admissions). Three per cent (243/8211) of IBD patients accounted for 50% of the total IBD bed‐days over the study period.Age‐standardised IBD admission rates fell from 39.4 to 25.5 admissions per 100,000 population between 2010 and 2019, an average annual percentage reduction of 3% (95% CI −4.5% to −2.1%, p < 0.0001). Non‐IBD admission rates were unchanged overall (145–137 per 100,000 population) and specifically for serious (hospitalisation) and severe (ITU admission or death) infection over the same period.Conclusion: Despite compounding prevalence and increased biologic use, IBD admission rates are falling. The cause of admission varies with age, with infection the predominant cause in older patients.
Objective Inflammatory bowel disease (IBD) colorectal cancer (CRC) surveillance aims to reduce cancer-associated mortality. We report outcomes of IBD-CRC colonoscopy surveillance, highlight missed surveillance opportunities and identify factors associated with dysplasia and CRC over a 10-year period at our centre. Methods Endoscopy software was interrogated for ‘IBD surveillance’ procedures from April 2008 to December 2018, to capture the surveillance cohort. Local databases were searched for all IBD-CRC cases outside surveillance. Follow-up was until August 2024. Results 1892 IBD surveillance colonoscopies from 1262 patients identified 144 cases of dysplasia (105/1892 sporadic; 16/1892 IBD-associated; 7/1892 indefinite for IBD-dysplasia; 16/1892 unspecified dysplasia aetiology). IBD-CRC was rare at 0.75 cases per 1000 patient years. Of the 21 IBD-CRC cases identified in this cohort, 8 were appropriately surveillance-detected within their correct surveillance interval. Of the remaining 13 cancers detected by other means, 7 were overdue surveillance. Factors associated with developing cancer were prior dysplasia (OR 10.84, 95% CI 4.46 to 26.36) (p<0.001), inflammatory pseudopolyps (OR 4.32, 95% CI 1.78 to 10.44) (p=0.001) and IBD disease duration (OR 1.04, 95% CI 1.002 to 1.08) (p=0.036). The 3-year postcolonoscopy CRC rate was 14.3%. Outside this surveillance cohort, 43 additional IBD-CRCs were identified; patients were more likely to have Crohn’s disease (p=0.040) and shorter disease duration (p<0.001). Cancer stage at presentation (p=0.609) and overall survival (p=0.679) was not different between the surveillance and non-surveillance cohorts. Conclusions In this real-world cohort, active surveillance did not improve cancer survival compared with patients whose cancer was detected by other means. A modern approach is needed to maximise the potential benefits of surveillance.